{"transactions":[{"id":4624345,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (Right to Buy)","published_at":"2026-09-18T21:04:53.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":85910,"price":0.582,"value":49999.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC (\"V-Co 4\"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein."}],"balance_after":85910,"derivative":{"exercise_price":0.456,"exercise_date":"2026-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":85910},"source":{"system":"sec-edgar","filing":"0001493152-26-043383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226043383/ownership.xml","form_type":"4"}},{"id":4624344,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Preferred Stock","published_at":"2026-09-18T21:04:53.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":85910,"price":0.582,"value":49999.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC (\"V-Co 4\"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein."}],"balance_after":85910,"source":{"system":"sec-edgar","filing":"0001493152-26-043383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226043383/ownership.xml","form_type":"4"}},{"id":674892,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-26T20:10:16.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0.41,"value":61500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2026 (the \"Grant Date\"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026."}],"balance_after":326533,"derivative":{"exercise_price":0.41,"expiration_date":"2036-07-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-26-040238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315226040238/ownership.xml","form_type":"4"}},{"id":674891,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:10:16.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0.41,"value":102500.0,"ownership":{"direct":true},"balance_after":250080,"source":{"system":"sec-edgar","filing":"0001493152-26-040238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315226040238/ownership.xml","form_type":"4"}},{"id":709205,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-15T20:23:47.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":2749330,"price":0.582,"value":1600110.06,"ownership":{"direct":false,"nature":"By V-Co Investors 4 LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":2749330,"derivative":{"exercise_price":0.456,"exercise_date":"2026-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":2749330},"source":{"system":"sec-edgar","filing":"0001193125-26-304815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000119312526304815/ownership.xml","form_type":"4"}},{"id":709204,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-07-15T20:23:47.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":1890164,"price":0.582,"value":1100075.448,"ownership":{"direct":false,"nature":"By V-Co Investors 4 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On June 30, 2026, V-Co Investors 4 LLC converted a bridge promissory note in the amount of $1,000,000 entered into between the reporting person and the Issuer into shares of the Issuer's Series A Convertible Preferred Stock, based on $0.456 per share plus $0.125 per share in accordance with the Nasdaq minimum price rules."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":2749330,"derivative":{"exercise_price":0.456,"underlying":"Common Stock","underlying_shares":1890164},"source":{"system":"sec-edgar","filing":"0001193125-26-304815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000119312526304815/ownership.xml","form_type":"4"}},{"id":709203,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-07-15T20:23:47.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":859166,"price":0.582,"value":500034.612,"ownership":{"direct":false,"nature":"By V-Co Investors 4 LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":859166,"derivative":{"exercise_price":0.456,"underlying":"Common Stock","underlying_shares":859166},"source":{"system":"sec-edgar","filing":"0001193125-26-304815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000119312526304815/ownership.xml","form_type":"4"}},{"id":820501,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52837,"kind":"organization","name":"V-Co Investors 3 LLC","position":2,"cik":"0002114460","reported_name":"V-Co Investors 3 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Warrant","published_at":"2026-04-02T23:34:11.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1783582,"price":1.34,"value":2389999.88,"ownership":{"direct":false,"nature":"By V-Co Investors 3 LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1783582,"derivative":{"exercise_price":1.09,"exercise_date":"2026-03-31","expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":1783582},"source":{"system":"sec-edgar","filing":"0002074003-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000207400326000008/ownership.xml","form_type":"4"}},{"id":820500,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52837,"kind":"organization","name":"V-Co Investors 3 LLC","position":2,"cik":"0002114460","reported_name":"V-Co Investors 3 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Stock Warrant","published_at":"2026-04-02T23:34:11.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1783582,"price":1.34,"value":2389999.88,"ownership":{"direct":false,"nature":"By V-CO Investors 3 LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1783582,"derivative":{"exercise_price":1.09,"exercise_date":"2026-03-31","expiration_date":"2028-03-31","underlying":"Common Stock","underlying_shares":1783582},"source":{"system":"sec-edgar","filing":"0002074003-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000207400326000008/ownership.xml","form_type":"4"}},{"id":820499,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52837,"kind":"organization","name":"V-Co Investors 3 LLC","position":2,"cik":"0002114460","reported_name":"V-Co Investors 3 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2026-04-02T23:34:11.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":429957,"price":1.34,"value":576142.38,"ownership":{"direct":false,"nature":"By V-CO Investors 3 LLC"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":429957,"derivative":{"exercise_price":0.0001,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":429957},"source":{"system":"sec-edgar","filing":"0002074003-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000207400326000008/ownership.xml","form_type":"4"}},{"id":820498,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52837,"kind":"organization","name":"V-Co Investors 3 LLC","position":2,"cik":"0002114460","reported_name":"V-Co Investors 3 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T23:34:11.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":308848,"price":1.34,"value":413856.32,"ownership":{"direct":false,"nature":"By V-CO Investors 3 LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1353625,"source":{"system":"sec-edgar","filing":"0002074003-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000207400326000008/ownership.xml","form_type":"4"}},{"id":820497,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":30368,"kind":"person","name":"Skaff Michael C","position":1,"cik":"0002074003","reported_name":"Skaff Michael C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52837,"kind":"organization","name":"V-Co Investors 3 LLC","position":2,"cik":"0002114460","reported_name":"V-Co Investors 3 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T23:34:11.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1044777,"price":1.34,"value":1400001.18,"ownership":{"direct":false,"nature":"By V-CO Investors 3 LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2026, V-Co Investors 3, LLC  converted a bridge promissory note in the amount of $1,400,000 entered into between the reporting person and the Issuer into shares of the Issuer's common stock, based on $1.09 per share of Common Stock plus $0.25 per share in accordance with the Nasdaq minimum price rules."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1044777,"source":{"system":"sec-edgar","filing":"0002074003-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2074003/000207400326000008/ownership.xml","form_type":"4"}},{"id":1348816,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:47:13.000Z","date":"2024-11-26","kind":"grant","planned":false,"acquired":true,"shares":315421,"price":2.64,"value":832711.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 7, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027."}],"balance_after":364755,"derivative":{"exercise_price":2.64,"expiration_date":"2034-09-07","underlying":"Common Stock","underlying_shares":315421},"source":{"system":"sec-edgar","filing":"0001493152-24-048026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224048026/ownership.xml","form_type":"4"}},{"id":1349235,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:43:54.000Z","date":"2024-11-26","kind":"grant","planned":false,"acquired":true,"shares":149533,"price":2.64,"value":394767.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 7, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters."}],"balance_after":180533,"derivative":{"exercise_price":2.64,"expiration_date":"2034-09-07","underlying":"Common Stock","underlying_shares":149533},"source":{"system":"sec-edgar","filing":"0001493152-24-048023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315224048023/ownership.xml","form_type":"4"}},{"id":1466957,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:51.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":2.38,"value":47600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 20, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 20,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028."}],"balance_after":49334,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-24-025688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224025688/ownership.xml","form_type":"4"}},{"id":1467634,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":37451,"kind":"person","name":"SOKOLOW LEONARD J","position":1,"cik":"0000923890","reported_name":"SOKOLOW LEONARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:50.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":2.38,"value":9520.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024."}],"balance_after":7467,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-24-025691","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/923890/000149315224025691/ownership.xml","form_type":"4"}},{"id":1466956,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89415,"kind":"person","name":"Green Ralph Elias","position":1,"cik":"0001835785","reported_name":"Green Ralph Elias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:47.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":2.38,"value":9520.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024."}],"balance_after":7067,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-24-025687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224025687/ownership.xml","form_type":"4"}},{"id":1467135,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:46.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":2.38,"value":35700.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 15,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028."}],"balance_after":31667,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-24-025686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315224025686/ownership.xml","form_type":"4"}},{"id":1466955,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89414,"kind":"person","name":"Lindsay Mark F.","position":1,"cik":"0001835542","reported_name":"Lindsay Mark F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:46.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":2.38,"value":9520.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024."}],"balance_after":7067,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-24-025690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224025690/ownership.xml","form_type":"4"}},{"id":1467252,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89434,"kind":"person","name":"Thompson Matthew","position":1,"cik":"0001740988","reported_name":"Thompson Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:53:49.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":2.38,"value":9520.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024."}],"balance_after":7067,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-24-025692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740988/000149315224025692/ownership.xml","form_type":"4"}},{"id":1467130,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89432,"kind":"person","name":"Krammer Anja B","position":1,"cik":"0001418077","reported_name":"Krammer Anja B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:53:47.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":2.38,"value":9520.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024."}],"balance_after":7067,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001493152-24-025689","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418077/000149315224025689/ownership.xml","form_type":"4"}},{"id":1848621,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-21T01:58:39.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":14000,"price":0.53,"value":7420.0,"ownership":{"direct":true},"balance_after":86521,"source":{"system":"sec-edgar","filing":"0001493152-23-021910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021910/ownership.xml","form_type":"4"}},{"id":1848618,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.53,"value":2650.0,"ownership":{"direct":true},"balance_after":72521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1848617,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.54,"value":5400.0,"ownership":{"direct":true},"balance_after":67521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1848616,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-15","kind":"purchase","planned":false,"acquired":true,"shares":21,"price":0.5,"value":10.5,"ownership":{"direct":true},"balance_after":57521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1853765,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-15T23:15:31.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.49,"value":4900.0,"ownership":{"direct":true},"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001493152-23-021525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021525/ownership.xml","form_type":"4"}},{"id":2075746,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":37451,"kind":"person","name":"SOKOLOW LEONARD J","position":1,"cik":"0000923890","reported_name":"SOKOLOW LEONARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:48.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":30000,"price":0.48,"value":14400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023."}],"balance_after":76667,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":76667},"source":{"system":"sec-edgar","filing":"0001493152-22-036730","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/923890/000149315222036730/ownership.xml","form_type":"4"}},{"id":2075364,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":150000,"price":0.48,"value":72000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026."}],"balance_after":483334,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":483334},"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2075363,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":333334,"price":0.48,"value":160000.32,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"333,334 fully vested stock options granted on December 23, 2022."}],"balance_after":333334,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":333334},"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2075362,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":20000,"price":0.5,"value":10000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager."}],"balance_after":47500,"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2075360,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89414,"kind":"person","name":"Lindsay Mark F.","position":1,"cik":"0001835542","reported_name":"Lindsay Mark F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:30.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":30000,"price":0.48,"value":14400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023."}],"balance_after":76667,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":76667},"source":{"system":"sec-edgar","filing":"0001493152-22-036728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036728/ownership.xml","form_type":"4"}},{"id":2075479,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:24.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":200000,"price":0.48,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"200,000 stock options granted on December 23, 2022. One-fifth vests annually on each anniversary date through December 23, 2026."}],"balance_after":500001,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":500001},"source":{"system":"sec-edgar","filing":"0001493152-22-036726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315222036726/ownership.xml","form_type":"4"}},{"id":2075359,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89415,"kind":"person","name":"Green Ralph Elias","position":1,"cik":"0001835785","reported_name":"Green Ralph Elias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:18.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":30000,"price":0.48,"value":14400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023."}],"balance_after":76667,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":76667},"source":{"system":"sec-edgar","filing":"0001493152-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036724/ownership.xml","form_type":"4"}},{"id":2075476,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89432,"kind":"person","name":"Krammer Anja B","position":1,"cik":"0001418077","reported_name":"Krammer Anja B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-28T21:45:50.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":30000,"price":0.48,"value":14400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023."}],"balance_after":76667,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":76667},"source":{"system":"sec-edgar","filing":"0001493152-22-036729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418077/000149315222036729/ownership.xml","form_type":"4"}},{"id":2075531,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89434,"kind":"person","name":"Thompson Matthew","position":1,"cik":"0001740988","reported_name":"Thompson Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-28T21:45:42.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":30000,"price":0.48,"value":14400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023."}],"balance_after":76667,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":76667},"source":{"system":"sec-edgar","filing":"0001493152-22-036725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740988/000149315222036725/ownership.xml","form_type":"4"}},{"id":2243616,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-03T10:08:33.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":4000,"price":1.83,"value":7320.0,"ownership":{"direct":true},"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001493152-22-015773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222015773/ownership.xml","form_type":"4"}},{"id":2243615,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-03T10:08:33.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":8000,"price":2.03,"value":16240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":23500,"source":{"system":"sec-edgar","filing":"0001493152-22-015773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222015773/ownership.xml","form_type":"4"}},{"id":2368249,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-28T23:54:57.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":125000,"price":3.27,"value":408750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"125,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026."}],"balance_after":125000,"derivative":{"exercise_price":3.27,"expiration_date":"2027-02-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-22-005662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222005662/ownership.xml","form_type":"4"}},{"id":2368777,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-28T23:50:54.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":50000,"price":3.27,"value":163500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026."}],"balance_after":50000,"derivative":{"exercise_price":3.27,"expiration_date":"2027-02-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-005660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315222005660/ownership.xml","form_type":"4"}},{"id":2397034,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T02:21:10.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":125000,"price":5.64,"value":705000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option for the purchase of 125,000 shares was granted on June 16, 2021. The option vests one fifth immediately and one-fifth annually on each anniversary date through June 16, 2025."}],"balance_after":125000,"derivative":{"exercise_price":5.64,"expiration_date":"2026-06-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-22-004603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222004603/ownership.xml","form_type":"5"}},{"id":2561447,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-22T19:09:28.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":5000,"price":4.31,"value":21550.0,"ownership":{"direct":true},"balance_after":15500,"source":{"system":"sec-edgar","filing":"0001493152-21-023354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221023354/ownership.xml","form_type":"4"}},{"id":2581466,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T01:27:19.000Z","date":"2018-10-22","kind":"grant","acquired":true,"shares":83334,"price":7.5,"value":625005.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"83,334 stock options granted on October 22, 2018. One-fifth vested immediately and one-fifth vests annually on each anniversary date through October 22, 2022"}],"balance_after":83334,"derivative":{"exercise_price":7.5,"expiration_date":"2023-10-22","underlying":"Common Stock","underlying_shares":83334},"source":{"system":"sec-edgar","filing":"0001493152-21-021915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221021915/ownership.xml","form_type":"4"}},{"id":2581465,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T01:27:19.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":16667,"price":7.5,"value":125002.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"16,667 stock options granted on November 18, 2019. One-fifth vested immediately and one-fifth vests annually on each anniversary date through November 18, 2023."}],"balance_after":16667,"derivative":{"exercise_price":7.5,"expiration_date":"2024-11-18","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001493152-21-021915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221021915/ownership.xml","form_type":"4"}},{"id":2581464,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T01:27:19.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":100000,"price":7.5,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025."}],"balance_after":100000,"derivative":{"exercise_price":7.5,"expiration_date":"2026-03-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-21-021915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221021915/ownership.xml","form_type":"4"}},{"id":2581463,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T01:27:19.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":50000,"price":5.26,"value":263000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50,000 stock options granted on August 31, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through August 31, 2025."}],"balance_after":50000,"derivative":{"exercise_price":5.26,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-021915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221021915/ownership.xml","form_type":"4"}},{"id":2597071,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-18T19:47:51.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":5000,"price":3,"value":15000.0,"ownership":{"direct":true},"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001493152-21-020536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221020536/ownership.xml","form_type":"4"}},{"id":2608037,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89415,"kind":"person","name":"Green Ralph Elias","position":1,"cik":"0001835785","reported_name":"Green Ralph Elias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T01:47:46.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221019255/ownership.xml","form_type":"4"}},{"id":2608036,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":136431,"kind":"person","name":"Singh Gurdev Dave","position":1,"cik":"0001835538","reported_name":"Singh Gurdev Dave","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T01:44:38.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221019251/ownership.xml","form_type":"4"}},{"id":2608035,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89414,"kind":"person","name":"Lindsay Mark F.","position":1,"cik":"0001835542","reported_name":"Lindsay Mark F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T01:43:17.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019249","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221019249/ownership.xml","form_type":"4"}},{"id":2609114,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":37451,"kind":"person","name":"SOKOLOW LEONARD J","position":1,"cik":"0000923890","reported_name":"SOKOLOW LEONARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T01:41:33.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/923890/000149315221019246/ownership.xml","form_type":"4"}},{"id":2608579,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89434,"kind":"person","name":"Thompson Matthew","position":1,"cik":"0001740988","reported_name":"Thompson Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-10T21:49:17.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1740988/000149315221019258/ownership.xml","form_type":"4"}},{"id":2608373,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":89432,"kind":"person","name":"Krammer Anja B","position":1,"cik":"0001418077","reported_name":"Krammer Anja B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-10T21:46:05.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":30000,"price":2.72,"value":81600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022."}],"balance_after":46667,"derivative":{"exercise_price":2.72,"expiration_date":"2026-08-05","underlying":"Common Stock","underlying_shares":46667},"source":{"system":"sec-edgar","filing":"0001493152-21-019253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418077/000149315221019253/ownership.xml","form_type":"4"}},{"id":2696833,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-26T01:45:31.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":1000,"price":5.29,"value":5290.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001493152-21-012902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221012902/ownership.xml","form_type":"4"}},{"id":2696485,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-26T01:45:20.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":4000,"price":5.38,"value":21520.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.335 to $5.40."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001493152-21-012901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221012901/ownership.xml","form_type":"4"}},{"id":2781899,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-03-18T00:48:47.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":100000,"price":7.5,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025."}],"balance_after":200001,"derivative":{"exercise_price":7.5,"expiration_date":"2026-03-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-21-006291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315221006291/ownership.xml","form_type":"4"}},{"id":2931193,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":19450,"kind":"person","name":"Amman Bradford K.","position":1,"cik":"0001425339","reported_name":"Amman Bradford K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-28T11:21:08.000Z","date":"2020-12-24","kind":"purchase","acquired":true,"shares":1000,"price":7.38,"value":7380.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001493152-20-024301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425339/000149315220024301/ownership.xml","form_type":"4"}},{"id":2932442,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-23T23:53:04.000Z","date":"2020-12-23","kind":"purchase","acquired":true,"shares":1000,"price":7.2669,"value":7266.9,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"1,000 shares purchased in prices ranging from $7.25 through $7.2798 per share."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001493152-20-024277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315220024277/ownership.xml","form_type":"4"}},{"id":2945853,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-14T13:45:32.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":500,"price":8.5,"value":4250.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001493152-20-023466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315220023466/ownership.xml","form_type":"4"}}]}